PET/CT colonography outperforms CT colonography for tumor staging

Article

The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.

The assumption that CT colonography is the logical choice for pairing with optical colonoscopy to stage colorectal cancer took a hit at the RSNA meeting today. A prospective study from Europe shows that whole-body FDG-PET/CT is significantly more accurate than CT colonography for staging colorectal tumors.

The study of 52 patients performed by Dr. Peter Veit at the University of Essen in Germany found that whole-body FDG-PET/CT colonography was 74% sensitive for T-staging, compared with a sensitivity rate for CT colonography of 52%. The results were confirmed by histopathology specimens and clinical follow-up 310 days after the initial evaluation. Veit has since joined the nuclear medicine residency program at the University of Zurich in Switzerland.

FDG-PET/CT colonography contributed to alteration of the clinical management of four patients, Veit said. In one instance, PET/CT colonography uncovered a second liver metastasis that was not detected with CT colonography alone. That finding identified the need for a second surgical session to resect the second lesion.

No significant differences in metastasis or lymph node staging were observed.

PET/CT colonography takes about seven minutes longer than the conventional 30-second PET/CT whole-body protocol for colorectal cancer staging, Veit said. Additional time is needed for pharmacological bowel relaxation and rectal water filling.

Recent Videos
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, Part 1
Addressing Cybersecurity Issues in Radiology
Computed Tomography Study Shows Emergence of Silicosis in Engineered Stone Countertop Workers
Can an Emerging AI Software for DBT Help Reduce Disparities in Breast Cancer Screening?
Skeletal Muscle Loss and Dementia: What Emerging MRI Research Reveals
Related Content
© 2025 MJH Life Sciences

All rights reserved.